Aeon Biopharma, Inc.

  • Earnings Score
  • Market Cap $25.44M
  • Debt $15.17M
  • Cash $537.00K
  • EV $40.07M
  • FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$124.65M
Equity-$32.09M
Growth Stability1
PE0.2
PEG0.01
PB-0.79
Price/Cash0.02
Debt/Equity-0.47
Earnings CAGR18%
Earnings Stability-0.74
Earnings Growth YoY-73%
Earnings Growth QoQ-104%
Earnings CAGR 5Y18%
Market Cap$25.44M
Assets$4.00M
Total Debt$15.17M
Cash$537.00K
Shares Outstanding38.39M
EV40.07M
Earnings Score6%
Working Capital-8.36M
Current Ratio0.22
Shares Growth 3y-3%
Equity Growth QoQ15%
Equity Growth YoY-74%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition.

SEC Filings

Direct access to Aeon Biopharma, Inc. (AEON) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Aeon Biopharma, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Aeon Biopharma, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 18%
Stability -74%
loading chart...

Aeon Biopharma, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Aeon Biopharma, Inc..

0
012345678910TV
fcf$0$0$0$0$0$0$0$0$0$0$0$0
DCF$0$0$0$0$0$0$0$0$0$0$0
Value$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/202012/202112/2022TTM
Net Margins----
ROA-3%4%-
ROE--48%557%-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/202012/202112/2022TTM
Debt over FCF----
Debt over Equity---13.91-0.47
Growth Stability---1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/202012/202112/2022CAGR 5Y
Revenue YoY growth----
Earnings YoY growth--229K%-741%18%
Equity YoY growth--79K%-44%-
FCF YoY growth----